SEC Comment Letter for Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX) — Jan 27, 2020
Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: Jan. 27, 2020 · CIK: 0001022899 · Accession: 0000000000-20-000676
AI Filing Summary & Sentiment
File numbers found in text: 000-51353
Letter
January 27, 2020 Alexander Arrow Chief Financial Officer Protagenic Therapeutics, Inc.\new 149 Fifth Avenue New York, New York 10010 Re:Protagenic Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2018 Filed March 29, 2019 File No. 000-51353 Dear Mr. Arrow: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Trade & Services
Show Raw Text
January 27, 2020
Alexander Arrow
Chief Financial Officer
Protagenic Therapeutics, Inc.\new
149 Fifth Avenue
New York, New York 10010
Re:Protagenic Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2018
Filed March 29, 2019
File No. 000-51353
Dear Mr. Arrow:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Trade & Services